Based on these data, tepotinib was granted Breakthrough Therapy Designation by the FDA in September 2019 for second-line treatment of patients with metastatic NSCLC harboring MET exon 14 skipping mutations who progressed following platinum-based cancer therapy. This evidence concerns the gene MET and cancer.